Heart Failure Associated with Onglyza™ and Kombiglyze® XR
In comparing three classes of medication for type 2 diabetes, researchers found one class, which includes the drugs Onglyza, Janumet and Januvia, did not reduce the risk of death.
Scientists from Imperial College London found that dipeptidyl peptidase inhibitors were not as effective as two others types when compared with a placebo: sodium-glucose cotransporter inhibitors, which include Jardiance and Invokana, and glucagon-like peptide agonists, which include Victoza, Byettea, Saxenda, Bydureon and Trulicity, and are used as injectables.
READ MORE at UPI.com
Dozens of lawsuits filed across the country against a diabetes drug have been transferred to U.S. District Court in Lexington.
More than 80 product-liability suits — 14 from New Jersey alone — have been transferred to U.S. District Judge Karen Caldwell’s oversight since Feb. 12. Two cases originated in Kentucky, which, according to the Center for Disease Control, has the fourth highest diabetes mortality rate in the nation.
READ MORE at the Lexington Herald Leader
A California woman alleges her mother sustained cardiac injuries as the result of taking two prescription drugs.
Lori Stewart, individually on behalf of the estate of Agnes Stewart, filed a complaint on March 29 in the U.S. District Court for the Eastern District of California against Bristol-Myers Squibb Co. and AstraZeneca Pharmaceuticals LP alleging wrongful death, negligence, failure to warn and other counts.
READ MORE at The Northern California Record
The diabetes drug Onglyza increases the risk of death from all causes, according to a U.S. Food and Drug Administration report released Friday.
FDA staff analyzed the findings of a clinical trial on the heart effects of AstraZeneca's drug for type 2 diabetes and found that it was associated with "significant or near-significant" increased risk of death from all causes, not just heart problems, Bloomberg News reported.
READ MORE at WebMD.com
As the waistline of Americans has increased, so has the incidence of Type 2 diabetes. Startling data from the Centers for Disease Control shows that that prevalence of this disease, which is directly related to obesity, now exceeds 9% in the adult population. It was less than half that rate in 1996. Furthermore, there doesn’t seem to be an end in sight. As the incidence of Type 2 diabetes increases, so will its sequelae: kidney failure, amputations and, eventually, heart attacks and strokes, all caused by the high levels of blood sugar endured by these patients. The increased burden to the healthcare system as a result of Type 2 diabetes will be with us for years to come.
READ MORE at Forbes.com